Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 5/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6919592 | 0.91 | HTR7 (0.57) | BCL2MCL1SRD5A2MAOB | |
| SCHEMBL27619992 | 0.89 | MCL1 (0.55) | BCL2MCL1SRD5A2PPARDPPARA | |
| SCHEMBL6385516 | 0.83 | ITGB3 (0.60) | BCL2MCL1SRD5A2PPARDPPARA | |
| SCHEMBL9200310 | 0.82 | SRD5A2 (0.53) | BCL2MCL1SRD5A2PPARDPPARA | |
| SCHEMBL6384598 | 0.82 | SRD5A2 (0.55) | BCL2MCL1SRD5A2PPARDPPARA | |
| SCHEMBL4191518 | 0.82 | MEN1 (0.54) | BCL2MCL1SRD5A2PPARDPPARA | |
| SCHEMBL27587634 | 0.81 | BCL2 (0.56) | BCL2MCL1SRD5A2PPARDPPARA | |
| SCHEMBL3862821 | 0.81 | PPARD (0.72) | SRD5A2PPARDPPARAKMT2A | |
| SCHEMBL17602263 | 0.80 | MEN1 (0.56) | BCL2MCL1SRD5A2PPARDPPARA | |
| SCHEMBL30395677 | 0.80 | PPARD (0.56) | BCL2MCL1SRD5A2PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486229-B2 | Indole derivative and application thereof | SHANGHAI MEDICILON INC. (CN) | 2025-12-02 | — | — | US | disclosed |
| US-20230357148-A1 | INDOLE DERIVATIVE AND APPLICATION THEREOF | SHANGHAI MEDICILON INC. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-7129250-B2 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2006-10-31 | — | — | US | disclosed |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-05-27 | — | — | US | disclosed |
| EP-1283836-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | Aegera Therapeutics Inc. (CA) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001087887-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | NLN, MKI67, BDNF | BCL2 18/4885MCL1 35/4885SRD5A2 2605/4885 |
| US-20230357148-A1 | INDOLE DERIVATIVE AND APPLICATION THEREOF | S1PR1, S1PR3, S1PR5 | BCL2 1727/4885MCL1 542/4885SRD5A2 786/4885 |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NLN, BDNF | BCL2 17/4885MCL1 40/4885SRD5A2 2387/4885 |
| US-12486229-B2 | Indole derivative and application thereof | S1PR1, S1PR3, S1PR5 | BCL2 1727/4885MCL1 542/4885SRD5A2 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.